Janus激酶抑制剂治疗一组难治性类风湿关节炎患者的较好结果:来自FIRST注册

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Arthritis Research & Therapy Pub Date : 2021-10-26 DOI:10.1186/s13075-022-02744-7

S. Ochi, K. Sonomoto, S. Nakayamada, Yoshiya Tanaka

引用次数: 23

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Arthritis Research & Therapy RHEUMATOLOGY-

CiteScore

8.30

自引率

2.00%

发文量

261

审稿时长

2.3 months

期刊介绍： Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports. A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care. Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.